Mundorf Thomas, Noecker Robert J, Earl Melissa
Private Practice, Charlotte, NC, USA.
Adv Ther. 2007 Mar-Apr;24(2):302-9. doi: 10.1007/BF02849898.
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite 0.15% (Alphagan P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan; Pfizer Inc., New York, NY( to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was > or =18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect )10 AM, or approximately 2 h after the morning dose of brimonidine 0.15%(. IOP at trough drug effect (8 AM, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (+/-2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P<.001) and 3.3 mm Hg (15%) at trough (P<.001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P<.001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.
本研究旨在评估0.15%的酒石酸溴莫尼定（阿法根0.15%；艾尔建公司，加利福尼亚州欧文市）作为0.005%拉坦前列素（适利达；辉瑞公司，纽约州纽约市）辅助治疗药物，用于开角型青光眼或高眼压症患者时的降眼压疗效。在这项多中心、开放标签的前瞻性评估中，43名入组患者在接受至少6周的拉坦前列素单药治疗后，眼压（IOP）≥18 mmHg。主要观察指标为药物效应峰值时（上午10点，即0.15%酒石酸溴莫尼定晨服后约2小时）的眼压。还测量了药物效应谷值时（上午8点，即酒石酸溴莫尼定晚服后约12小时）的眼压。基线眼压为21.9（±2.3）mmHg。治疗1个月后，与拉坦前列素治疗的基线值相比，药物效应峰值时平均眼压进一步降低5.8 mmHg（26%）（P<0.001），药物效应谷值时降低3.3 mmHg（15%）（P<0.001）。在第2个月就诊时，与拉坦前列素治疗的基线值相比，药物效应峰值时平均眼压进一步降低5.1 mmHg（23%）（P<0.001），药物效应谷值时降低2.0 mmHg（9%）（P = 0.002）。0.15%的酒石酸溴莫尼定与拉坦前列素治疗的基线值相比，能使眼压在统计学上显著进一步降低。这些研究结果表明，对于需要进一步降低眼压的拉坦前列素治疗患者，0.15%的酒石酸溴莫尼定是一种有效的辅助治疗药物。
